Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Journal of Medical Postgraduates ; (12): 104-108, 2018.
Artículo en Chino | WPRIM | ID: wpr-700783

RESUMEN

Glucose transporters protein (GLUTs) is the main carrier of glucose transport in mammalian cells, in which GLUT1 is the most widely distributed in glucose transporter in vivo. Studies have shown that GLUT1 has abnormally high expression in urinary tract tumors such as renal cell carcinoma,prostate cancer,bladder cancer and nephroblastoma,cleading to increased intracellu-lar glucose uptake,which is closely related to tumor occurrence,evolution,invasion,prognosis and drug resistance. As a new target of tumor therapy,GLUT1 has attracted extensive attention. This review summarizes the recent advances on the expression of GLUT1 in tumor and its mechanism,which can provide a new perspective for the treatment and prognosis evaluation of tumor.

2.
Chinese Journal of Urology ; (12)2000.
Artículo en Chino | WPRIM | ID: wpr-541148

RESUMEN

ObjectiveTo evaluate the therapeutic effect and toxicities of gemcitabine combined with cisplatin in the treatment of advanced or metastatic transitional cell carcinoma (TCC) of urinary tract. Methods Eighteen patients with advanced or metastatic TCC of urinary tract (15 cases of bladder TCC,2 of renal pelvic TCC,and 1 of ureteral TCC),who were pathologically confirmed,were treated with GC regimen (gemcitabine 1000 mg/m 2,iv infusion on day 1 and day 8;cisplatin 30 mg/m 2,iv infusion on day 2,day 8 and day 9).Before treatment, Karnofsy score for each patient was evaluated with a result of ≥60;liver and renal functions and blood routine test were normal.GC regimen was repeated for 2-3 cycles every 3-4 weeks and the response rate was evaluated.ResultsThree patients (16.7%) had complete response; 7(38.9%), partial response;5(27.8%),no response;and 3(16.7%) had progression.The overall response rate was 55.6%. The main toxic effects included decrease in white cell count (10 cases),anemia (7),nausea and vomiting (10) and constipation (8),which were mild or moderate and disappeared after stopping treatment.No chemotherapy-associated death occurred.ConclusionsGemcitabine combined with cisplatin in the treatment of advanced or metastatic transitional cell carcinoma of urinary tract is effective,and the toxicity is mild and tolerated. It is suggested that GC regimen can be used as the first line chemotherapy.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA